{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:24:56Z","timestamp":1792196696408,"version":"4.4.0"},"reference-count":239,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002742","name":"IOE","doi-asserted-by":"publisher","award":["R\/Dev\/D\/IOE\/Incentive\/2021-22\/32275"],"award-info":[{"award-number":["R\/Dev\/D\/IOE\/Incentive\/2021-22\/32275"]}],"id":[{"id":"10.13039\/501100002742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Leishmaniasis, a category 1 neglected protozoan disease caused by a kinetoplastid pathogen called Leishmania, is transmitted through dipteran insect vectors (phlebotomine, sand flies) in three main clinical forms: fatal visceral leishmaniasis, self-healing cutaneous leishmaniasis, and mucocutaneous leishmaniasis. Generic pentavalent antimonials have long been the drug of choice against leishmaniasis; however, their success is plagued with limitations such as drug resistance and severe side effects, which makes them redundant as frontline therapy for endemic visceral leishmaniasis. Alternative therapeutic regimens based on amphotericin B, miltefosine, and paromomycin have also been approved. Due to the unavailability of human vaccines, first-line chemotherapies such as pentavalent antimonials, pentamidine, and amphotericin B are the only options to treat infected individuals. The higher toxicity, adverse effects, and perceived cost of these pharmaceutics, coupled with the emergence of parasite resistance and disease relapse, makes it urgent to identify new, rationalized drug targets for the improvement in disease management and palliative care for patients. This has become an emergent need and more relevant due to the lack of information on validated molecular resistance markers for the monitoring and surveillance of changes in drug sensitivity and resistance. The present study reviewed the recent advances in chemotherapeutic regimens by targeting novel drugs using several strategies including bioinformatics to gain new insight into leishmaniasis. Leishmania has unique enzymes and biochemical pathways that are distinct from those of its mammalian hosts. In light of the limited number of available antileishmanial drugs, the identification of novel drug targets and studying the molecular and cellular aspects of these drugs in the parasite and its host is critical to design specific inhibitors targeting and controlling the parasite. The biochemical characterization of unique Leishmania-specific enzymes can be used as tools to read through possible drug targets. In this review, we discuss relevant metabolic pathways and novel drugs that are unique, essential, and linked to the survival of the parasite based on bioinformatics and cellular and biochemical analyses.<\/jats:p>","DOI":"10.3390\/pathogens12050706","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T09:56:18Z","timestamp":1683885378000},"page":"706","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host"],"prefix":"10.3390","volume":"12","author":[{"given":"Ranjeet","family":"Singh","sequence":"first","affiliation":[{"name":"Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-2340","authenticated-orcid":false,"given":"Mohammad","family":"Kashif","sequence":"additional","affiliation":[{"name":"Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India"},{"name":"School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi 110067, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India"},{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-0818","authenticated-orcid":false,"given":"Partha Pratim","family":"Manna","sequence":"additional","affiliation":[{"name":"Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1586\/14787210.2015.1056160","article-title":"Leishmaniasis: Diagnostic Issues in Europe","volume":"13","author":"Torpiano","year":"2015","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_3","unstructured":"(2022, November 05). Leishmaniasis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","article-title":"The History of Leishmaniasis","volume":"10","author":"Steverding","year":"2017","journal-title":"Parasites Vectors"},{"key":"ref_5","unstructured":"Melby, P.C., Travi, B.L., and Yaneth Osorio, E. (2019). Encyclopedia of Microbiology, Elsevier."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.mib.2010.05.008","article-title":"Flagellum Assembly and Function during the Leishmania Life Cycle","volume":"13","author":"Gluenz","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/pgmj.2006.047340corr1","article-title":"Leishmaniasis","volume":"83","author":"Piscopo","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Songumpai, N., Promrangsee, C., Noopetch, P., Siriyasatien, P., and Preativatanyou, K. (2022). First Evidence of Co-Circulation of Emerging Leishmania Martiniquensis, Leishmania Orientalis, and Crithidia Sp. in Culicoides Biting Midges (Diptera: Ceratopogonidae), the Putative Vectors for Autochthonous Transmission in Southern Thailand. Trop. Med. Infect. Dis., 7.","DOI":"10.3390\/tropicalmed7110379"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4269\/ajtmh.22-0108","article-title":"Case Report: Autochthonous Disseminated Cutaneous, Mucocutaneous, and Visceral Leishmaniasis Caused by Leishmania Martiniquensis in a Patient with HIV\/AIDS from Northern Thailand and Literature Review","volume":"107","author":"Srivarasat","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Alvar, J., and Arana, B.I. (2017). Appraisal of Leishmaniasis Chemotherapy, Current Status and Pipeline StrategiesChapter 1 Leishmaniasis, Impact and Therapeutic Needs, Royal Society of Chemistry.","DOI":"10.1039\/9781788010177-00001"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32376","DOI":"10.1039\/C5RA02669E","article-title":"Antileishmanial Drug Discovery: Comprehensive Review of the Last 10 Years","volume":"5","author":"Sangshetti","year":"2015","journal-title":"RSC Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1086\/314896","article-title":"Evidence That the High Incidence of Treatment Failures in Indian Kala-Azar Is Due to the Emergence of Antimony-Resistant Strains of Leishmania Donovani","volume":"180","author":"Lira","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of Pentavalent Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian Epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Meheus, F., Balasegaram, M., Olliaro, P., Sundar, S., Rijal, S., Faiz, M.A., and Boelaert, M. (2010). Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000818"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The Activity of Alkyl Phosphorylcholines and Related Derivatives against Leishmania Donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral Miltefosine for Indian Visceral Leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing Failure of Miltefosine in the Treatment of Kala-Azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1086\/322689","article-title":"Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent","volume":"33","author":"Soto","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4269\/ajtmh.2008.78.210","article-title":"Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis","volume":"78","author":"Soto","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pinart, M., Rueda, J.-R., Romero, G.A., Pinz\u00f3n-Fl\u00f3rez, C.E., Osorio-Arango, K., Maia-Elkhoury, A.N.S., Reveiz, L., Elias, V.M., and Tweed, J.A. (2020). Interventions for American Cutaneous and Mucocutaneous Leishmaniasis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004834.pub3"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.316.7139.1200","article-title":"Randomised Controlled Trial of Aminosidine (Paromomycin) v Sodium Stibogluconate for Treating Visceral Leishmaniasis in North Bihar, India","volume":"316","author":"Jha","year":"1998","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable Paromomycin for Visceral Leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hailu, A., Musa, A., Wasunna, M., Balasegaram, M., Yifru, S., Mengistu, G., Hurissa, Z., Hailu, W., Weldegebreal, T., and Tesfaye, S. (2010). Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000709"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Musa, A.M., Younis, B., Fadlalla, A., Royce, C., Balasegaram, M., Wasunna, M., Hailu, A., Edwards, T., Omollo, R., and Mudawi, M. (2010). Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000855"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, O.L., Diaz-Toro, Y., Ovalle, C., Valderrama, L., Muvdi, S., Rodr\u00edguez, I., Gomez, M.A., and Saravia, N.G. (2014). Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002871"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1021\/cr400552x","article-title":"Fruitful Decade for Antileishmanial Compounds from 2002 to Late 2011","volume":"114","author":"Hussain","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678707.2019.1552853","article-title":"Leishmaniasis: Treatment, Drug Resistance and Emerging Therapies","volume":"7","author":"Sundar","year":"2019","journal-title":"Expert. Opin. Orphan Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14787210.2018.1483720","article-title":"Prospects for Antimicrobial Peptide-Based Immunotherapy Approaches in Leishmania Control","volume":"16","author":"Zahedifard","year":"2018","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.2174\/0929867323666160909155222","article-title":"Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients","volume":"23","author":"Rafferty","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the Use of Therapeutic Peptides for Cancer Treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-981-13-3588-4_15","article-title":"Clinical Application of AMPs","volume":"1117","author":"Costa","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2018.02.055","article-title":"A Novel Synthetic Peptide Inspired on Lys49 Phospholipase A2 from Crotalus Oreganus Abyssus Snake Venom Active against Multidrug-Resistant Clinical Isolates","volume":"149","author":"Almeida","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_36","first-page":"868","article-title":"Antimicrobial Peptides for Leishmaniasis","volume":"11","author":"Cobb","year":"2010","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2174\/138945012802002393","article-title":"Antimicrobial Peptide Action on Parasites","volume":"13","author":"Torrent","year":"2012","journal-title":"Curr. Drug. Targets"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/AAC.02328-15","article-title":"Identification of Synthetic and Natural Host Defense Peptides with Leishmanicidal Activity","volume":"60","author":"Marr","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/978-1-60761-594-1_25","article-title":"Characterization of the Leishmanicidal Activity of Antimicrobial Peptides","volume":"618","author":"Rivas","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, U., Pinart, M., Reveiz, L., and Alvar, J. (2008). Interventions for Old World Cutaneous Leishmaniasis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD005067.pub3"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0031182017002116","article-title":"Chemotherapeutics of Visceral Leishmaniasis: Present and Future Developments","volume":"145","author":"Sundar","year":"2018","journal-title":"Parasitology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Passero, L.F.D., Brunelli, E.D.S., Sauini, T., Amorim Pavani, T.F., Jesus, J.A., and Rodrigues, E. (2021). The Potential of Traditional Knowledge to Develop Effective Medicines for the Treatment of Leishmaniasis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.690432"},{"key":"ref_43","first-page":"9","article-title":"Current Treatment of Leishmaniasis: A Review","volume":"1","author":"Monzote","year":"2009","journal-title":"Open. Antimicrob. Agents J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral Leishmaniasis Treatment: What Do We Have, What Do We Need and How to Deliver It?","volume":"2","author":"Chatelain","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actatropica.2015.12.016","article-title":"Visceral Leishmaniasis: Revisiting Current Treatments and Approaches for Future Discoveries","volume":"155","author":"No","year":"2016","journal-title":"Acta Trop."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2174\/1389200217666160819161444","article-title":"Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis","volume":"17","author":"Singh","year":"2016","journal-title":"Curr. Drug. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M.P., L\u00f3pez-V\u00e9lez, R., Garc\u00eda-Hern\u00e1ndez, R., Pountain, A.W., Mwenechanya, R., and Papadopoulou, B. (2017). Drug Resistance and Treatment Failure in Leishmaniasis: A 21st Century Challenge. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006052"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rivas, L., and Gil, G. (2018). Drug Discovery for Leishmaniasis, Royal Society of Chemistry.","DOI":"10.1039\/9781788010177"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Alves, F., Bilbe, G., Blesson, S., Goyal, V., Monnerat, S., Mowbray, C., Muthoni Ouattara, G., P\u00e9coul, B., Rijal, S., and Rode, J. (2018). Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clin. Microbiol. Rev., 31.","DOI":"10.1128\/CMR.00048-18"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2741\/4629","article-title":"Leishmaniasis Treatment: Update of Possibilities for Drug Repurposing","volume":"23","author":"Pereira","year":"2018","journal-title":"Front. Biosci. Landmark"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1515\/pac-2018-1102","article-title":"Current and Promising Novel Drug Candidates against Visceral Leishmaniasis","volume":"91","author":"Reguera","year":"2019","journal-title":"Pure Appl. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of Leishmaniasis: Present Challenges","volume":"145","author":"Uliana","year":"2018","journal-title":"Parasitology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/156802661903190328155136","article-title":"Leishmaniasis and Chagas Disease-Neglected Tropical Diseases: Treatment Updates","volume":"19","author":"Sangenito","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.idc.2018.10.005","article-title":"Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens","volume":"33","author":"Diro","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"622286","DOI":"10.3389\/fchem.2021.622286","article-title":"An Overview on the Therapeutics of Neglected Infectious Diseases\u2014Leishmaniasis and Chagas Diseases","volume":"9","author":"J","year":"2021","journal-title":"Front. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00436-021-07139-2","article-title":"Leishmaniasis: Where Are We and Where Are We Heading?","volume":"120","author":"Sasidharan","year":"2021","journal-title":"Parasitol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/520665","article-title":"Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions","volume":"45","author":"Sundar","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1258\/td.2008.080369","article-title":"Severe Adverse Reactions to Meglumine Antimoniate in the Treatment of Visceral Leishmaniasis: A Report of 13 Cases in the Southwestern Region of Brazil","volume":"39","author":"Brustoloni","year":"2009","journal-title":"Trop. Doct."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Sundar, S., Singh, A., Tiwari, A., Shukla, S., Chakravarty, J., and Rai, M. (2014). Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. ISRN Parasitol., 2014.","DOI":"10.1155\/2014\/548010"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"de Menezes, J.P.B., Guedes, C.E.S., de Oliveira Almeida Petersen, A.L., Fraga, D.B.M., and Veras, P.S.T. (2015). Advances in Development of New Treatment for Leishmaniasis. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/815023"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.2005.72.133","article-title":"Comparison of Meglumine Antimoniate and Pentamidine for Peruvian Cutaneous Leishmaniasis","volume":"72","author":"Andersen","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10096-011-1276-0","article-title":"Leishmaniasis: New Insights from an Old and Neglected Disease","volume":"31","author":"Antinori","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/14756360802208137","article-title":"Development of New Antileishmanial Drugs--Current Knowledge and Future Prospects","volume":"23","year":"2008","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B Formulations and Drug Targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1128\/AAC.00639-13","article-title":"Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis","volume":"57","author":"Fernandes","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1128\/AAC.00352-16","article-title":"A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania Donovani Parasites Both In Vitro and In Vivo by Targeting Type IB Topoisomerase","volume":"60","author":"Saha","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exppara.2019.01.011","article-title":"Anti-Leishmanial Effect of Spiro Dihydroquinoline-Oxindoles on Volume Regulation Decrease and Sterol Biosynthesis of Leishmania Braziliensis","volume":"198","author":"Sojo","year":"2019","journal-title":"Exp. Parasitol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1007\/s00436-015-4618-5","article-title":"Antileishmanial Effect of Mevastatin Is Due to Interference with Sterol Metabolism","volume":"114","author":"Dinesh","year":"2015","journal-title":"Parasitol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Singh, S., Babu, N.K., Singh, S., and Babu, N.K. (2018). 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGR) Enzyme of the Sterol Biosynthetic Pathway: A Potential Target against Visceral Leishmaniasis, IntechOpen.","DOI":"10.5772\/intechopen.75480"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/jcb.29922","article-title":"Targeting Sterol Alpha-14 Demethylase of Leishmania Donovani to Fight against Leishmaniasis","volume":"122","author":"Tabrez","year":"2021","journal-title":"J. Cell Biochem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exppara.2017.02.015","article-title":"Glycyrrhizic Acid Attenuates Growth of Leishmania Donovani by Depleting Ergosterol Levels","volume":"176","author":"Dinesh","year":"2017","journal-title":"Exp. Parasitol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1515\/ap-2017-0070","article-title":"In Vitro Effects of Purine and Pyrimidine Analogues on Leishmania Donovani and Leishmania Infantum Promastigotes and Intracellular Amastigotes","volume":"62","author":"Azzouz","year":"2017","journal-title":"Acta Parasitol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"29954","DOI":"10.1074\/jbc.M113.478826","article-title":"Substrate Inhibition of Uracil Phosphoribosyltransferase by Uracil Can Account for the Uracil Growth Sensitivity of Leishmania Donovani Pyrimidine Auxotrophs","volume":"288","author":"Soysa","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15416\/pcpr.v5i3.29380","article-title":"Anti-Malarial Drugs as Potential Inhibitors of Leishmania Glycolytic Enzymes: Development of New Anti-Leishmanial Agents","volume":"5","author":"Yousef","year":"2020","journal-title":"Pharmacol. Clin. Pharm. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1007\/s00436-019-06404-9","article-title":"Artemisinin-Resistant Leishmania Parasite Modulates Host Cell Defense Mechanism and Exhibits Altered Expression of Unfolded Protein Response Genes","volume":"118","author":"Verma","year":"2019","journal-title":"Parasitol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00436-019-06443-2","article-title":"Need for Sustainable Approaches in Antileishmanial Drug Discovery","volume":"118","author":"Hendrickx","year":"2019","journal-title":"Parasitol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41429-019-0240-6","article-title":"Trimethoprim and Other Nonclassical Antifolates an Excellent Template for Searching Modifications of Dihydrofolate Reductase Enzyme Inhibitors","volume":"73","author":"Arciszewska","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/cmb.2019.0332","article-title":"Identification of Selective Inhibitors of LdDHFR Enzyme Using Pharmacoinformatic Methods","volume":"28","author":"Sharma","year":"2021","journal-title":"J. Comput. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.4155\/fmc-2018-0512","article-title":"Targeting Pteridine Reductase 1 and Dihydrofolate Reductase: The Old Is a New Trend for Leishmaniasis Drug Discovery","volume":"11","author":"Kagami","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/1062936X.2019.1684357","article-title":"Structure Based Designing of Benzimidazole\/Benzoxazole Derivatives as Anti-Leishmanial Agents","volume":"30","author":"Kapil","year":"2019","journal-title":"SAR QSAR Environ. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00018-017-2653-3","article-title":"Ammonium Trichloro [1,2-Ethanediolato-O,O\u2032]-Tellurate Cures Experimental Visceral Leishmaniasis by Redox Modulation of Leishmania Donovani Trypanothione Reductase and Inhibiting Host Integrin Linked PI3K\/Akt Pathway","volume":"75","author":"Vishwakarma","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Pramanik, P.K., Chakraborti, S., Bagchi, A., and Chakraborti, T. (2020). Bioassay-Based Corchorus Capsularis L. Leaf-Derived \u03b2-Sitosterol Exerts Antileishmanial Effects against Leishmania Donovani by Targeting Trypanothione Reductase. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-77066-2"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/cbdd.13022","article-title":"Molecular Events Leading to Death of Leishmania Donovani under Spermidine Starvation after Hypericin Treatment","volume":"90","author":"Singh","year":"2017","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.04169-14","article-title":"Probing the Molecular Mechanism of Hypericin-Induced Parasite Death Provides Insight into the Role of Spermidine beyond Redox Metabolism in Leishmania Donovani","volume":"59","author":"Singh","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the Treatment and Control of Leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv. Parasitol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0304-4017(02)00115-2","article-title":"Chemotherapy of Canine Leishmaniosis","volume":"106","author":"Baneth","year":"2002","journal-title":"Vet. Parasitol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Haldar, A.K., Sen, P., and Roy, S. (2011). Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions. Mol. Biol. Int., 2011.","DOI":"10.4061\/2011\/571242"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/AAC.37.9.1842","article-title":"Antileishmanial Activity of Sodium Stibogluconate Fractions","volume":"37","author":"Roberts","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1074\/jbc.M005423200","article-title":"Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania Donovani","volume":"276","author":"Ulrich","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"39925","DOI":"10.1074\/jbc.M405635200","article-title":"Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania Donovani","volume":"279","author":"Wyllie","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12551-013-0134-y","article-title":"Antimony Transport Mechanisms in Resistant Leishmania Parasites","volume":"6","author":"Reis","year":"2014","journal-title":"Biophys. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1128\/AAC.47.10.3073-3079.2003","article-title":"Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites","volume":"47","author":"Brochu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1365-2958.2005.04782.x","article-title":"Modulation in Aquaglyceroporin AQP1 Gene Transcript Levels in Drug-Resistant Leishmania","volume":"57","author":"Marquis","year":"2005","journal-title":"Mol. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/jac\/dkp468","article-title":"Assessing Aquaglyceroporin Gene Status and Expression Profile in Antimony-Susceptible and -Resistant Clinical Isolates of Leishmania Donovani from India","volume":"65","author":"Mandal","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"26301","DOI":"10.1074\/jbc.M102351200","article-title":"The Leishmania ATP-Binding Cassette Protein PGPA Is an Intracellular Metal-Thiol Transporter ATPase","volume":"276","author":"Richard","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/AAC.00211-13","article-title":"A New ABC Half-Transporter in Leishmania Major Is Involved in Resistance to Antimony","volume":"57","author":"Manzano","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Rai, S., Goel, S.K., Dwivedi, U.N., Sundar, S., and Goyal, N. (2013). Role of Efflux Pumps and Intracellular Thiols in Natural Antimony Resistant Isolates of Leishmania Donovani. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074862"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1086\/341406","article-title":"A Randomized, Double-Blind Study of the Efficacy of a 10- or 20-Day Course of Sodium Stibogluconate for Treatment of Cutaneous Leishmaniasis in United States Military Personnel","volume":"35","author":"Wortmann","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic Review of the Adverse Effects of Cutaneous Leishmaniasis Treatment in the New World","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Wise, E.S., Armstrong, M.S., Watson, J., and Lockwood, D.N. (2012). Monitoring Toxicity Associated with Parenteral Sodium Stibogluconate in the Day-Case Management of Returned Travellers with New World Cutaneous Leishmaniasis [Corrected]. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/annotation\/15ab4f39-31e7-40bc-9b15-6e90a612b49a"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.34.2.183","article-title":"Amphotericin B: Current Understanding of Mechanisms of Action","volume":"34","author":"Brajtburg","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002329900086","article-title":"Amphotericin B Kills Unicellular Leishmanias by Forming Aqueous Pores Permeable to Small Cations and Anions","volume":"152","author":"Ramos","year":"1996","journal-title":"J. Membr. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","article-title":"Liposomal Amphotericin B Treatment of Cutaneous Leishmaniasis Due to Leishmania Tropica","volume":"25","author":"Solomon","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_106","first-page":"11","article-title":"Lipsosomal Amphotericin B: A Review of Its Properties, Function, and Use for Treatment of Cutaneous Leishmaniasis","volume":"10","author":"Shirzadi","year":"2019","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/cid\/civ416","article-title":"Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B","volume":"61","author":"Machado","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Romero, G.A.S., Costa, D.L., Costa, C.H.N., de Almeida, R.P., de Melo, E.V., de Carvalho, S.F.G., Rabello, A., de Carvalho, A.L., de Queiroz Sousa, A., and Leite, R.D. (2017). Efficacy and Safety of Available Treatments for Visceral Leishmaniasis in Brazil: A Multicenter, Randomized, Open Label Trial. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005706"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exppara.2018.02.003","article-title":"Comparing the Therapeutic Efficacy of Different Amphotericin B-Carrying Delivery Systems against Visceral Leishmaniasis","volume":"186","author":"Martins","year":"2018","journal-title":"Exp. Parasitol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2217\/nnm.14.182","article-title":"Targeted Chemotherapy of Visceral Leishmaniasis by Lactoferrin-Appended Amphotericin B-Loaded Nanoreservoir: In Vitro and in Vivo Studies","volume":"10","author":"Asthana","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Faustino, C., and Pinheiro, L. (2020). Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010029"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A Review of Its Pharmacology and Therapeutic Efficacy in the Treatment of Leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1128\/AAC.01123-06","article-title":"Miltefosine Affects Lipid Metabolism in Leishmania Donovani Promastigotes","volume":"51","author":"Rakotomanga","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India after a Decade of Use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijantimicag.2011.11.008","article-title":"Efficacy of Miltefosine Treatment in Leishmania Amazonensis-Infected BALB\/c Mice","volume":"39","author":"Godinho","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Coelho, A.C., Oliveira, J.C., Espada, C.R., Reim\u00e3o, J.Q., Trinconi, C.T., and Uliana, S.R.B. (2016). A Luciferase-Expressing Leishmania Braziliensis Line That Leads to Sustained Skin Lesions in BALB\/c Mice and Allows Monitoring of Miltefosine Treatment Outcome. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004660"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Coelho, A.C., Trinconi, C.T., Costa, C.H.N., and Uliana, S.R.B. (2016). In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania Amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004720"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1590\/S0074-02762011000400015","article-title":"The in Vitro Leishmanicidal Activity of Hexadecylphosphocholine (Miltefosine) against Four Medically Relevant Leishmania Species of Brazil","volume":"106","author":"Damasceno","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/AAC.47.8.2397-2403.2003","article-title":"Leishmania Donovani Resistance to Miltefosine Involves a Defective Inward Translocation of the Drug","volume":"47","author":"Castanys","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Deep, D.K., Singh, R., Bhandari, V., Verma, A., Sharma, V., Wajid, S., Sundar, S., Ramesh, V., Dujardin, J.C., and Salotra, P. (2017). Increased Miltefosine Tolerance in Clinical Isolates of Leishmania Donovani Is Associated with Reduced Drug Accumulation, Increased Infectivity and Resistance to Oxidative Stress. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005641"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4269\/ajtmh.18-0949","article-title":"Natural Resistance of Leishmania Infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil","volume":"101","author":"Carnielli","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13071-017-1969-z","article-title":"Laboratory Confirmed Miltefosine Resistant Cases of Visceral Leishmaniasis from India","volume":"10","author":"Srivastava","year":"2017","journal-title":"Parasit. Vectors"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Chawla, B., Jhingran, A., Panigrahi, A., Stuart, K.D., and Madhubala, R. (2011). Paromomycin Affects Translation and Vesicle-Mediated Trafficking as Revealed by Proteomics of Paromomycin -Susceptible -Resistant Leishmania Donovani. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026660"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sinha, P.K., Jha, T.K., Thakur, C.P., Nath, D., Mukherjee, S., Aditya, A.K., and Sundar, S. (2011). Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India. J. Trop. Med., 2011.","DOI":"10.1155\/2011\/645203"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug Resistance in Indian Visceral Leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pt.2011.04.001","article-title":"Urban Parasitology: Visceral Leishmaniasis in Brazil","volume":"27","author":"Harhay","year":"2011","journal-title":"Trends Parasitol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1179\/000349803225002516","article-title":"HIV and the Transmission of Leishmania","volume":"97","author":"Molina","year":"2003","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(05)70296-6","article-title":"Treatment Options for Visceral Leishmaniasis: A Systematic Review of Clinical Studies Done in India, 1980\u20132004","volume":"5","author":"Olliaro","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"31010","DOI":"10.1074\/jbc.M403959200","article-title":"Drug Uptake and Modulation of Drug Resistance in Leishmania by an Aquaglyceroporin","volume":"279","author":"Gourbal","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1073\/pnas.93.19.10383","article-title":"Trypanothione Overproduction and Resistance to Antimonials and Arsenicals in Leishmania","volume":"93","author":"Mukhopadhyay","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1093\/emboj\/16.11.3057","article-title":"Co-Amplification of the Gamma-Glutamylcysteine Synthetase Gene Gsh1 and of the ABC Transporter Gene PgpA in Arsenite-Resistant Leishmania Tarentolae","volume":"16","author":"Grondin","year":"1997","journal-title":"EMBO J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/expr.1997.4222","article-title":"Efflux Systems and Increased Trypanothione Levels in Arsenite-ResistantLeishmania","volume":"87","author":"Papadopoulou","year":"1997","journal-title":"Exp. Parasitol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1093\/nar\/gkg806","article-title":"Modulation of Gene Expression in Leishmania Drug Resistant Mutants as Determined by Targeted DNA Microarrays","volume":"31","author":"Guimond","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"do Monte-Neto, R.L., Coelho, A.C., Raymond, F., L\u00e9gar\u00e9, D., Corbeil, J., Melo, M.N., Fr\u00e9zard, F., and Ouellette, M. (2011). Gene Expression Profiling and Molecular Characterization of Antimony Resistance in Leishmania Amazonensis. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001167"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug Resistance in Leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/jac\/dku534","article-title":"Up-Regulation of Silent Information Regulator 2 (Sir2) Is Associated with Amphotericin B Resistance in Clinical Isolates of Leishmania Donovani","volume":"70","author":"Purkait","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.42.2.352","article-title":"Mechanism of Amphotericin B Resistance in Leishmania Donovani Promastigotes","volume":"42","author":"Mbongo","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Rai, K., Cuypers, B., Bhattarai, N.R., Uranw, S., Berg, M., Ostyn, B., Dujardin, J.-C., Rijal, S., and Vanaerschot, M. (2013). Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting Leishmania Donovani Strain. mBio, 4.","DOI":"10.1128\/mBio.00611-13"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of Miltefosine in Visceral Leishmaniasis Is Associated With Low Drug Exposure","volume":"210","author":"Dorlo","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1128\/AAC.01415-06","article-title":"Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in Leishmania Donovani Promastigotes","volume":"51","author":"Rivas","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1128\/AAC.00587-08","article-title":"Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid Movement","volume":"52","author":"Gamarro","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Coelho, A.C., Trinconi, C.T., Costa, C.H.N., and Uliana, S.R.B. (2014). In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania Amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002999"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1128\/AAC.01694-08","article-title":"Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania Braziliensis Refractory to the Drug","volume":"53","author":"Carvalho","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/AAC.01023-13","article-title":"Treatment Failure and Miltefosine Susceptibility in Dermal Leishmaniasis Caused by Leishmania Subgenus Viannia Species","volume":"58","author":"Obonaga","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpddr.2015.05.006","article-title":"Leishmania Is Not Prone to Develop Resistance to Tamoxifen","volume":"5","author":"Coelho","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00436-014-3755-6","article-title":"Comparative Transcript Expression Analysis of Miltefosine-Sensitive and Miltefosine-Resistant Leishmania Donovani","volume":"113","author":"Kulshrestha","year":"2014","journal-title":"Parasitol. Res."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Mondelaers, A., Sanchez-Ca\u00f1ete, M.P., Hendrickx, S., Eberhardt, E., Garcia-Hernandez, R., Lachaud, L., Cotton, J., Sanders, M., Cuypers, B., and Imamura, H. (2016). Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania Infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154101"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/mmi.13291","article-title":"In Vitro Selection of Miltefosine Resistance in Promastigotes of Leishmania Donovani from Nepal: Genomic and Metabolomic Characterization","volume":"99","author":"Shaw","year":"2016","journal-title":"Mol. Microbiol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/AAC.46.12.3731-3738.2002","article-title":"Resistance to Pentamidine in Leishmania Mexicana Involves Exclusion of the Drug from the Mitochondrion","volume":"46","author":"Basselin","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0166-6851(03)00162-2","article-title":"Functional Genetic Identification of PRP1, an ABC Transporter Superfamily Member Conferring Pentamidine Resistance in Leishmania Major","volume":"130","author":"Ac","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"E3012","DOI":"10.1073\/pnas.1520693113","article-title":"Cos-Seq for High-Throughput Identification of Drug Target and Resistance Mechanisms in the Protozoan Parasite Leishmania","volume":"113","author":"Gazanion","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.2012.12-0022","article-title":"In Vitro Antileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis--Status of Newly Introduced Drugs","volume":"87","author":"Prajapati","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/infdis\/jiv354","article-title":"Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania Braziliensis in Peru and Bolivia","volume":"213","author":"Adaui","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiv355","article-title":"Presence of Leishmania RNA Virus 1 in Leishmania Guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse","volume":"213","author":"Bourreau","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of Short-Course Multidrug Treatment with Standard Therapy for Visceral Leishmaniasis in India: An Open-Label, Non-Inferiority, Randomised Controlled Trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The Relationship between Leishmaniasis and AIDS: The Second 10 Years","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(12)70348-1","article-title":"HIV-1 Protease Inhibitors for Treatment of Visceral Leishmaniasis in HIV-Co-Infected Individuals","volume":"13","author":"Diro","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/civ530","article-title":"Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India","volume":"61","author":"Mahajan","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Burza, S., Mahajan, R., Sinha, P.K., van Griensven, J., Pandey, K., Lima, M.A., Sanz, M.G., Sunyoto, T., Kumar, S., and Mitra, G. (2014). Visceral Leishmaniasis and HIV Co-Infection in Bihar, India: Long-Term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome). PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003053"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.drudis.2016.01.011","article-title":"Integrating Biophysics with HTS-Driven Drug Discovery Projects","volume":"21","author":"Folmer","year":"2016","journal-title":"Drug. Discovery Today"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cbpa.2017.03.017","article-title":"Combinatorial Chemistry in Drug Discovery","volume":"38","author":"Liu","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.drudis.2015.12.007","article-title":"In Silico Methods to Address Polypharmacology: Current Status, Applications and Future Perspectives","volume":"21","author":"Lavecchia","year":"2016","journal-title":"Drug. Discov. Today"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1208\/s12248-012-9322-0","article-title":"Structure-Based Virtual Screening for Drug Discovery: A Problem-Centric Review","volume":"14","author":"Cheng","year":"2012","journal-title":"AAPS J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/aps.2012.109","article-title":"Computational Drug Discovery","volume":"33","author":"Lu","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"D457","DOI":"10.1093\/nar\/gkp851","article-title":"TriTrypDB: A Functional Genomic Resource for the Trypanosomatidae","volume":"38","author":"Aslett","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/978-1-61779-827-6_17","article-title":"LeishCyc: A Guide to Building a Metabolic Pathway Database and Visualization of Metabolomic Data","volume":"881","author":"Saunders","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/dnares\/dst031","article-title":"The Genome Sequence of Leishmania (Leishmania) Amazonensis: Functional Annotation and Extended Analysis of Gene Models","volume":"20","author":"Real","year":"2013","journal-title":"DNA Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"D98","DOI":"10.1093\/nar\/gkr1032","article-title":"GeneDB--an Annotation Database for Pathogens","volume":"40","author":"Boehme","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"D581","DOI":"10.1093\/nar\/gkw1105","article-title":"EuPathDB: The Eukaryotic Pathogen Genomics Database Resource","volume":"45","author":"Aurrecoechea","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.gdata.2015.12.012","article-title":"LmSmdB: An Integrated Database for Metabolic and Gene Regulatory Network in Leishmania Major and Schistosoma Mansoni","volume":"7","author":"Patel","year":"2016","journal-title":"Genom. Data"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Dikhit, M.R., Moharana, K.C., Sahoo, B.R., Sahoo, G.C., and Das, P. (2014). LeishMicrosatDB: Open Source Database of Repeat Sequences Detected in Six Fully Sequenced Leishmania Genomes. Database, 2014.","DOI":"10.1093\/database\/bau078"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Gazestani, V.H., Yip, C.W., Nikpour, N., Berghuis, N., and Salavati, R. (2017). TrypsNetDB: An Integrated Framework for the Functional Characterization of Trypanosomatid Proteins. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005368"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Torres, F., Arias-Carrasco, R., Caris-Maldonado, J.C., Barral, A., Maracaja-Coutinho, V., and De Queiroz, A.T.L. (2017). LeishDB: A Database of Coding Gene Annotation and Non-Coding RNAs in Leishmania Braziliensis. Database, 2017.","DOI":"10.1093\/database\/bax047"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Waugh, B., Ghosh, A., Bhattacharyya, D., Ghoshal, N., and Banerjee, R. (2014). In Silico Work Flow for Scaffold Hopping in Leishmania. BMC Res. Notes, 7.","DOI":"10.1186\/1756-0500-7-802"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/msb.2008.15","article-title":"Systems Analysis of Metabolism in the Pathogenic Trypanosomatid Leishmania Major","volume":"4","author":"Chavali","year":"2008","journal-title":"Mol. Syst. Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-Dependent Kinase 12 Is a Drug Target for Visceral Leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"590544","DOI":"10.3389\/fphar.2020.590544","article-title":"In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania Amazonensis","volume":"11","author":"Silva","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ijantimicag.2018.12.011","article-title":"In Silico Studies and Evaluation of Antiparasitic Role of a Novel Pyruvate Phosphate Dikinase Inhibitor in Leishmania Donovani Infected Macrophages","volume":"53","author":"Kashif","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Kashif, M., Paladhi, A., Singh, R., Bhattacharyya, S., Hira, S.K., and Manna, P.P. (2020). Leishmanicidal Activity of an In Silico-Screened Novel Inhibitor against Ascorbate Peroxidase of Leishmania Donovani. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01766-19"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/10799893.2016.1171344","article-title":"Structure-Based Virtual Screening, Molecular Docking, ADMET and Molecular Simulations to Develop Benzoxaborole Analogs as Potential Inhibitor against Leishmania Donovani Trypanothione Reductase","volume":"37","author":"Pandey","year":"2017","journal-title":"J. Recept. Signal. Transduct. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10822-016-9921-4","article-title":"Drug Search for Leishmaniasis: A Virtual Screening Approach by Grid Computing","volume":"30","author":"Ochoa","year":"2016","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/EBC20170052","article-title":"Structure-Based Drug Design: Aiming for a Perfect Fit","volume":"61","author":"Workman","year":"2017","journal-title":"Essays Biochem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular Docking and Structure-Based Drug Design Strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.genrep.2017.09.003","article-title":"Recent Advancement and Treatment of Leishmaniasis Based on Pharmacoinformatics Approach: Current and Future Outlook","volume":"9","author":"Ansari","year":"2017","journal-title":"Gene Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.1074\/jbc.M110.209593","article-title":"Dissecting the Metabolic Roles of Pteridine Reductase 1 in Trypanosoma Brucei and Leishmania Major*","volume":"286","author":"Ong","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Casgrain, P.-A., Martel, C., McMaster, W.R., Mottram, J.C., Olivier, M., and Descoteaux, A. (2016). Cysteine Peptidase B Regulates Leishmania Mexicana Virulence through the Modulation of GP63 Expression. PLoS Pathogens, 12.","DOI":"10.1371\/journal.ppat.1005658"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/cbdd.13326","article-title":"Discovery of Benzimidazole-Based Leishmania Mexicana Cysteine Protease CPB2.8\u0394CTE Inhibitors as Potential Therapeutics for Leishmaniasis","volume":"92","author":"Ferro","year":"2018","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Marreiros, B.C., Sena, F.V., Sousa, F.M., Oliveira, A.S.F., Soares, C.M., Batista, A.P., and Pereira, M.M. (2017). Structural and Functional Insights into the Catalytic Mechanism of the Type II NADH:Quinone Oxidoreductase Family. Sci. Rep., 7.","DOI":"10.1038\/srep42303"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Stevanovi\u0107, S., Perdih, A., Sen\u0107anski, M., Gli\u0161i\u0107, S., Duarte, M., Tom\u00e1s, A.M., Sena, F.V., Sousa, F.M., Pereira, M.M., and Solmajer, T. (2018). In Silico Discovery of a Substituted 6-Methoxy-Quinalidine with Leishmanicidal Activity in Leishmania Infantum. Molecules, 23.","DOI":"10.3390\/molecules23040772"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.biochi.2012.04.003","article-title":"Crystal Structure of Dihydroorotate Dehydrogenase from Leishmania Major","volume":"94","author":"Cordeiro","year":"2012","journal-title":"Biochimie"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Mamidala, R., Majumdar, P., Jha, K.K., Bathula, C., Agarwal, R., Chary, M.T., Majumder, H.K., Munshi, P., and Sen, S. (2016). Identification of Leishmania Donovani Topoisomerase 1 Inhibitors via Intuitive Scaffold Hopping and Bioisosteric Modification of Known Top 1 Inhibitors. Sci. Rep., 6.","DOI":"10.1038\/srep26603"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of Eukaryotic Topoisomerases in Transcription, Replication and Genomic Stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Fiorillo, A., Colotti, G., Boffi, A., Baiocco, P., and Ilari, A. (2012). The Crystal Structures of the Tryparedoxin-Tryparedoxin Peroxidase Couple Unveil the Structural Determinants of Leishmania Detoxification Pathway. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001781"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2174\/1568026611313090002","article-title":"A Novel Integrated Framework and Improved Methodology of Computer-Aided Drug Design","volume":"13","author":"Chen","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chemolab.2015.06.016","article-title":"Chemometrics Tools in QSAR\/QSPR Studies: A Historical Perspective","volume":"149","author":"Yousefinejad","year":"2015","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/jcb.26433","article-title":"Identification of Novel Inhibitors against UDP-Galactopyranose Mutase to Combat Leishmaniasis","volume":"119","author":"Kashif","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_198","first-page":"120","article-title":"The Screening of Novel Inhibitors against Leishmania Donovani Calcium Ion Channel to Fight Leishmaniasis","volume":"16","author":"Kashif","year":"2016","journal-title":"Infect. Disord. Drug. Targets (Former. Curr. Drug. Targets Infect. Disord.)"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"32989","DOI":"10.1074\/jbc.M114.569434","article-title":"Gluconeogenesis in Leishmania Mexicana: Contribution of Glycerol Kinase, Phosphoenolpyruvate Carboxykinase, and Pyruvate Phosphate Dikinase","volume":"289","author":"Hamilton","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12539-011-0109-2","article-title":"Preliminary Analysis to Target Pyruvate Phosphate Dikinase from Wolbachia Endosymbiont of Brugia Malayi for Designing Anti-Filarial Agents","volume":"4","author":"Palayam","year":"2012","journal-title":"Interdiscip. Sci. Comput. Life Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10822-007-9159-2","article-title":"An Improved Relaxed Complex Scheme for Receptor Flexibility in Computer-Aided Drug Design","volume":"22","author":"Amaro","year":"2008","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_202","unstructured":"Wu, C., Dunaway-Mariano, D., and Mariano, P.S. (2022, November 10). Design, Synthesis, and Evaluation of Inhibitors of Pyruvate Phosphate Dikinase. Available online: https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/jo3018473."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/EC.4.6.1147-1154.2005","article-title":"Eukaryotic UDP-Galactopyranose Mutase (GLF Gene) in Microbial and Metazoal Pathogens","volume":"4","author":"Beverley","year":"2005","journal-title":"Eukaryotic Cell."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbrc.2011.03.057","article-title":"Isolation and Characterization of Functional Leishmania Major Virulence Factor UDP-Galactopyranose Mutase","volume":"407","author":"Oppenheimer","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/AAC.02834-14","article-title":"Ascorbate Peroxidase, a Key Molecule Regulating Amphotericin B Resistance in Clinical Isolates of Leishmania Donovani","volume":"58","author":"Kumar","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/EC.00198-09","article-title":"Overexpression of Mitochondrial Leishmania Major Ascorbate Peroxidase Enhances Tolerance to Oxidative Stress-Induced Programmed Cell Death and Protein Damage","volume":"8","author":"Dolai","year":"2009","journal-title":"Eukaryotic Cell."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Pal, S., Dolai, S., Yadav, R.K., and Adak, S. (2010). Ascorbate Peroxidase from Leishmania Major Controls the Virulence of Infective Stage of Promastigotes by Regulating Oxidative Stress. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011271"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jprot.2013.01.011","article-title":"Proteome Changes Associated with Leishmania Donovani Promastigote Adaptation to Oxidative and Nitrosative Stresses","volume":"81","author":"Sardar","year":"2013","journal-title":"J. Proteom."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jmb.2014.05.022","article-title":"Specific Inhibition of P97\/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase Domains","volume":"426","author":"Chou","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cmdc.201200520","article-title":"Structure\u2013Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of P97 ATPase","volume":"8","author":"Chou","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1073\/pnas.1015312108","article-title":"Reversible Inhibitor of P97, DBeQ, Impairs Both Ubiquitin-Dependent and Autophagic Protein Clearance Pathways","volume":"108","author":"Chou","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Guedes Aguiar, B., Padmanabhan, P.K., Dumas, C., and Papadopoulou, B. (2018). Valosin-Containing Protein VCP\/P97 Is Essential for the Intracellular Development of Leishmania and Its Survival under Heat Stress. Cell. Microbiol., 20.","DOI":"10.1111\/cmi.12867"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00232154","article-title":"Role of Ca2+ Ion on Leishmania-Macrophage Attachment","volume":"102","author":"Misra","year":"1991","journal-title":"Mol. Cell. Biochem."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ceca.2011.03.003","article-title":"Calcium and Cell Death Mechanisms: A Perspective from the Cell Death Community","volume":"50","author":"Zhivotovsky","year":"2011","journal-title":"Cell. Calcium"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Batool, M., Ahmad, B., and Choi, S. (2019). A Structure-Based Drug Discovery Paradigm. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112783"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00436-020-06736-x","article-title":"An Overview of Biochemically Characterized Drug Targets in Metabolic Pathways of Leishmania Parasite","volume":"119","author":"Raj","year":"2020","journal-title":"Parasitol. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/ja8018687","article-title":"Inhibitors of UDP-Galactopyranose Mutase Thwart Mycobacterial Growth","volume":"130","author":"Dykhuizen","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2174\/1381612811319140007","article-title":"Targeting UDP-Galactopyranose Mutases from Eukaryotic Human Pathogens","volume":"19","author":"Kizjakina","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s000180300021","article-title":"Galactofuranose Metabolism: A Potential Target for Antimicrobial Chemotherapy","volume":"60","author":"Pedersen","year":"2003","journal-title":"CMLS Cell. Mol. Life Sci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1534\/genetics.107.073148","article-title":"A Novel Screening Method for Cell Wall Mutants in Aspergillus Niger Identifies UDP-Galactopyranose Mutase as an Important Protein in Fungal Cell Wall Biosynthesis","volume":"178","author":"Damveld","year":"2008","journal-title":"Genetics"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1128\/EC.00109-08","article-title":"Contribution of Galactofuranose to the Virulence of the Opportunistic Pathogen Aspergillus Fumigatus","volume":"7","author":"Schmalhorst","year":"2008","journal-title":"Eukaryotic Cell."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1074\/jbc.M700023200","article-title":"Targeted Gene Deletion of Leishmania Major UDP-Galactopyranose Mutase Leads to Attenuated Virulence","volume":"282","author":"Kleczka","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Misra, S., Valicherla, G.R., Shahab, M., Gupta, J., Gayen, J.R., and Misra-Bhattacharya, S. (2016). UDP-Galactopyranose Mutase, a Potential Drug Target against Human Pathogenic Nematode Brugia Malayi. Pathog. Dis., 74.","DOI":"10.1093\/femspd\/ftw072"},{"key":"ref_224","first-page":"1","article-title":"Ascorbate Peroxidase Overexpression Protects Leishmania Braziliensis against Trivalent Antimony Effects","volume":"113","author":"Xavier","year":"2018","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.redox.2017.03.004","article-title":"Deciphering the Interplay between Cysteine Synthase and Thiol Cascade Proteins in Modulating Amphotericin B Resistance and Survival of Leishmania Donovani under Oxidative Stress","volume":"12","author":"Singh","year":"2017","journal-title":"Redox Biol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"629","DOI":"10.16943\/ptinsa\/2015\/v81i3\/48223","article-title":"The Complex World of Cellular Defense in the Leishmania Parasite","volume":"81","author":"Das","year":"2015","journal-title":"Proc. Indian. Natl. Sci. Acad."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20050311","article-title":"Leishmania Major Encodes an Unusual Peroxidase That Is a Close Homologue of Plant Ascorbate Peroxidase: A Novel Role of the Transmembrane Domain","volume":"390","author":"Adak","year":"2005","journal-title":"Biochem. J."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.freeradbiomed.2008.08.029","article-title":"Leishmania Major Ascorbate Peroxidase Overexpression Protects Cells against Reactive Oxygen Species-Mediated Cardiolipin Oxidation","volume":"45","author":"Dolai","year":"2008","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/cdd.2014.103","article-title":"Inhibition of Autophagy, Lysosome and VCP Function Impairs Stress Granule Assembly","volume":"21","author":"Seguin","year":"2014","journal-title":"Cell. Death Differ."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Mansuri, R., Kumar, A., Rana, S., Panthi, B., Ansari, M.Y., Das, S., Dikhit, M.R., Sahoo, G.C., and Das, P. (2017). In Vitro Evaluation of Antileishmanial Activity of Computationally Screened Compounds against Ascorbate Peroxidase To Combat Amphotericin B Drug Resistance. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02429-16"},{"key":"ref_231","first-page":"257","article-title":"Energy Production in Entamoeba Histolytica: New Perspectives in Rational Drug Design","volume":"27","year":"1996","journal-title":"Arch. Med. Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00894-018-3791-8","article-title":"Virtual Screening to Identify Leishmania Braziliensis N-Myristoyltransferase Inhibitors: Pharmacophore Models, Docking, and Molecular Dynamics","volume":"24","author":"Santana","year":"2018","journal-title":"J. Mol. Model."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"353","DOI":"10.6026\/97320630010353","article-title":"Tryparedoxin Peroxidase of Leishmania Braziliensis: Homology Modeling and Inhibitory Effects of Flavonoids for Anti-Leishmanial Activity","volume":"10","author":"Gundampati","year":"2014","journal-title":"Bioinformation"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12539-011-0101-x","article-title":"Screening Natural Products Database for Identification of Potential Antileishmanial Chemotherapeutic Agents","volume":"3","author":"Venkatesan","year":"2011","journal-title":"Interdiscip. Sci."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Maamri, S., Benarous, K., and Yousfi, M. (2021). Identification of 3-Methoxycarpachromene and Masticadienonic Acid as New Target Inhibitors against Trypanothione Reductase from Leishmania Infantum Using Molecular Docking and ADMET Prediction. Molecules, 26.","DOI":"10.3390\/molecules26113335"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Inacio, J.D.F., Fonseca, M.S., Limaverde-Sousa, G., Tomas, A.M., Castro, H., and Almeida-Amaral, E.E. (2021). Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania Infantum, Causing Alterations in Redox Balance and Leading to Parasite Death. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.640561"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4274\/tjps.galenos.2021.53367","article-title":"Discovery of Novel Pyruvate Kinase Inhibitors Against Leishmania Major Among FDA Approved Drugs Through System Biology and Molecular Docking Approach","volume":"18","author":"Ranjbar","year":"2021","journal-title":"Turk. J. Pharm. Sci."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly Accurate Protein Structure Prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/5\/706\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:51Z","timestamp":1760124831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/5\/706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":239,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["pathogens12050706"],"URL":"https:\/\/doi.org\/10.3390\/pathogens12050706","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}